sign in sign up
<<
Home , Filgotinib, Lorlatinib

NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Date of Technology appraisal (TA) Time to Date of TA Release with this medical condition, as indicated by local local (hyperlinked) Yes N/A implement NICE decision due decision days (90 days) made

Evidence-based recommendations on sotagliflozin with for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin TA622 – Sotagliflozin with therapy. insulin for treating type 1 12th February 2020 Y 12/05/2020 20/05/2020 98 days CCG Commissioned diabetes Note: Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. Therefore the period of time the NHS has to comply with these recommendations has been extended (see the section on implementation) TA623 – Patiromer for treating Evidence based recommendations on hyperkalaemia patiromer (Veltassa) for treating 13th February 2020 Y 13/05/2020 20/05/2020 97 days hyperkalaemia in adults. CCG Commissioned TA624 – Peginterferon- beta 1a Evidence-based recommendations on for treating relapsed-remitting peginterferon beta-1a (Plegridy) for multiple sclerosis 19th February 2020 treating relapsing–remitting multiple Y 20/05/2020 20/05/2020 91 days sclerosis in adults. NHS England Commissioned TA597 – Dapagliflozin with Evidence-based recommendations on insulin for treating type 1 dapagliflozin (Forxiga) with insulin for diabetes 12th February 2020 treating type 1 diabetes not controlled by Y 13/05/2020 20/05/2020 98 days updated insulin therapy alone in adults with a body mass index (BMI) of at least 27 kg/m2. CCG Commissioned TA625 – Recombinant human NICE is unable to make a recommendation parathyroid hormone for 4th March 2020 on recombinant human parathyroid treating hypoparathyroidism [terminated hormone for treating hypoparathyroidism N/A N/A N/A appraisal] because Shire Pharmaceuticals (now part N/A of Takeda) did not provide an evidence submission TA627 – with Evidence-based recommendations on for previously lenalidomide (Revlimid) with rituximab for treated follicular 7th April 2020 previously treated follicular lymphoma Y 06/07/2020 20/05/2020 43 days (grade 1 to 3A) in adults. NHS England Commissioned TA628 – for Evidence-based recommendations on previously treated ALK-positive lorlatinib (Lorviqua) for previously treated Y advanced non-small-cell lung 13th May 2020 ALK-positive advanced non-small-cell lung 11/08/2020 17/06/2020 35 days

cancer cancer in adults. NHS England Commissioned TA629 – with Evidence-based recommendations on bendamustine for trearing obinutuzumab (Gazyvaro) with follicular lymphoma after bendamustine for follicular lymphoma that rituximab has not responded or has progressed up to 13th May 2020 Y 11/08/2020 17/06/2020 35 days 6 months after treatment with rituximab or a rituximab-containing regimen in adults. Cancer Drugs Fund TA630 – for Evidence-based recommendations on treating NTRK fusion-positive larotrectinib (Vitrakvi) for treating solid tumours neurotrophic tyrosine receptor 27th May 2020 Y 28/08/2020 17/06/2020 21 days (NTRK) fusion-positive solid tumours in adults and children. Cancer Drugs Fund TA626 – Avatrombopag for Evidence-based recommendations on treating in avatrombopag (Doptelet) for treating people with chronic liver severe thrombocytopenia in adults with 24th June 2020 Y 22/09/2020 15/07/2020 21 days disease needing a planned chronic liver disease needing a planned invasive procedure invasive procedure. CCG Commissioned

NICE TA Adherence checklist 2020/2021 ELHE NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Date of Technology appraisal (TA) Time to Date of TA Release with this medical condition, as indicated by local local (hyperlinked) Yes N/A implement NICE decision due decision days (90 days) made

Evidence-based recommendations on TA631 – Fremanezumab for fremanezumab (Ajovy) for preventing preventing chronic migraine in 3rd June 2020 chronic migraine in adults. Y 01/09/2020 15/07/2020 42 days adults CCG Commissioned. BlueTeq form required TA632 – Evidence-based recommendations on emtansine for adjuvant (Kadcyla) for treatnment of HER2-positive human epidermal 2 early breast cancer (HER2)-positive early breast cancer in 10th June 2020 adults who have residual invasive disease Y 08/09/2020 15/07/2020 35 days in the breast or lymph nodes after neoadjuvant taxane-based and HER2-. NHS England Commissioned TA633 – for Evidence-based recommendations on treating moderately to severe ustekinumab (Stelara) for treating active ulcerative colitis moderately to severely active ulcerative 17th June 2020 Y 15/09/2020 15/07/2020 28 days colitis in adults. CCG Commissioned. BlueTeq form required TA634 – with NICE is unable to make a recommendation lenalidomide and on daratumumab (Darzalex) with for untreated 30th June 2020 lenalidomide and dexamethasone for multiple myeloma [terminated untreated multiple myeloma, because N/A N/A N/A N/A appraisal] Janssen did not provide an evidence submission.

TA635 – with NICE is unable to make a recommendation for untreated EGFR on ramucirumab (Cyramza) with erlotinib positive metastatic non-small- for untreated cell lung cancer 30th June 2020 receptor (EGFR)-positive metastatic non- [terminated small-cell lung cancer, because Eli Lilly and N/A N/A N/A N/A appraisal] Company Limited did not provide an evidence submission.

TA636 – Eclulizumab for NICE is unable to make a recommendation treating refractory myasthenia 30th June 2020 on (Soliris) for treating gravis. [terminated refractory myasthenia gravis because N/A N/A N/A N/A appraisal] Alexion Pharma UK did not provide an evidence submission. TA638 – with Evidence-based recommendations on carboplatin and etoposide for atezolizumab (Tecentriq) for untreated untreated extensive-stage 1st July 2020 extensive-stage small-cell lung cancer in Y 29/09/2020 19/08/2020 49 days small-cell lung cancer adults. NHS England Commissioned TA639 – Atezolizumab with Evidence-based recommendations on nab-paclitaxel for untreated atezolizumab (Tecentriq) with PD-L1-positive, locally nab-paclitaxel for triple-negative, advanced or metastatic, triple- unresectable, PD-L1-positive, locally 1st July 2020 Y 29/09/2020 19/08/2020 49 days negative breast cancer advanced or metastatic breast cancer in adults who have not had for metastatic disease. NHS England Commissioned

NICE TA Adherence checklist 2020/2021 ELHE NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Technology appraisal (TA) Y Time to Date of TA Release with this medical condition, as indicated by local Date of local (hyperlinked) e N/A implement NICE decision due decision made s days (90 days)

TA640 - Treosulfan with Evidence-based recommendations on fludarabine for malignant treosulfan (Trecondi) with fludarabine for disease before allogenic stem conditioning treatment before allogeneic cell transplant haematopoietic stem cell transplant for 5th August 2020 Y 03/11/2020 16/09/2020 42 days malignant diseases in people for whom a reduced intensity regimen would be suitable. NHS England Commissioned TA641 – Evidence-based recommendations on in combination for untreated brentuximab vedotin (Adcetris) with systemic anaplastic large cell cyclophosphamide, doxorubicin and 12th August 2020 Y 10/11/2020 16/09/2020 35 days lymphoma prednisone for untreated systemic anaplastic large cell lymphoma in adults. NHS England Commissioned TA642 – for treating Evidence-based recommendations on relapsed or refractory acute gilteritinib (Xospata) for relapsed or myeloid leukaemia 12th August 2020 refractory FLT3-mutation-positive acute Y 10/11/2020 16/09/2020 35 days myeloid leukaemia in adults. NHS England Commissioned TA643 – for Evidence-based recommendations on treating ROS1-positive entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung advanced non-small-cell lung cancer 12th August 2020 Y 10/11/2020 16/09/2020 35 days cancer (NSCLC) in adults who have not had ROS1 inhibitors. NHS England Commissioned TA644 – Entrectinib for Evidence-based recommendations on treating neurotrophic tyrosine entrectinib (Rozlytrek) for treating receptor kinase fusion-positive neurotrophic tyrosine receptor kinase 12th August 2020 Y 10/11/2020 16/09/2020 35 days solid tumours in adults and (NTRK) fusion-positive solid tumours in children over 12 years adults and children over 12 years. Cancer Drugs Fund TA645 – with Evidence-based recommendations on for untreated avelumab (Bavencio) with axitinib (Inlyta) 2nd Sept 2020 Y 01/12/2020 21/10/2020 49 days advanced renal cell carcinoma for untreated advanced renal cell carcinoma in adults. TA646 – with NICE is unable to make a recommendation chemotherapy for untreated on glasdegib with chemotherapy for 2nd Sept 2020 acute myeloid leukaemia untreated acute myeloid leukaemia because N/A N/A N/A N/A [terminated appraisal] did not provide an evidence submission. TA647 – Eculizumab for NICE is unable to make a recommendation treating relapsing on eculizumab (Soliris) for treating relapsing 2nd Sept 2020 neuromyelitis optica neuromyelitis optica because Alexion N/A N/A N/A N/A [terminated appraisal] Pharma UK did not provide an evidence submission. TA648 – Dupilumab for NICE is unable to make a recommendation treating chronic rhinosinusitis on dupilumab (Dupixent) for treating 9th Sept 2020 with nasal polyps chronic rhinosinusitis with nasal polyps N/A N/A N/A N/A [terminated appraisal] because Sanofi did not provide an evidence submission. TA649 - Polatuzumabvedotin Evidence-based recommendations on with rituximab and (Polivy) with rituximab bendamustine for treating and bendamustine for treating relapsed or relapsed or refractory diffuse 23rd Sept 2020 refractory diffuse large B-cell lymphoma in Y 22/12/2020 21/10/20 28 days large B-cell lymphoma adults who cannot have a haematopoietic stem cell transplant. NHS England Commissioned TA650 – with Evidence-based recommendations on axitinib for untreated advanced pembrolizumab (Keytruda) with axitinib 30th Sept 2020 Y 22/12/2020 21/10/20 21days renal cell cancer carcinoma (Inlyta) for untreated advanced renal cell carcinoma in adults.

NICE TA Adherence checklist 2020/2021 ELHE NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Technology appraisal (TA) Y Time to Date of TA Release with this medical condition, as indicated by local Date of local (hyperlinked) e N/A implement NICE decision due decision made s days (90 days)

TA651 – Naldemedine for Evidence-based recommendations on treating opioid-induced naldemedine (Rizmoic) for treating opioid- th constipation 30 Sept 2020 induced constipation in adults who have Y 29/12/2020 21/10/20 21 days had laxative treatment. CCG Commissioned TA652 – Alpelisib with NICE is unable to make a recommendation fulvestrant for treating on alpelisib (Piqray) with fulvestrant for

hormone-receptor positive, 7th October 2020 treating hormone-receptor positive, HER2- N/A N/A N/A HER2-negative, PIK3CA-positive [terminated appraisal] negative, PIK3CA-positive advanced breast N/A

advanced breast cancer cancer because Novartis did not provide an evidence submission. TA653 – Osimertiib for treating Evidence-based recommendations on EGFR T790M mutation-positive (Tagrisso) for treating epidermal advanced non-small-cell lung growth factor receptor (EGFR) T790M cancer 14th October 2020 mutation-positive locally advanced or Y 12/01/2021 18/11/2020 35 days metastatic non-small-cell lung cancer (NSCLC) in adults. NHS England Commissioned TA654 – Osimertinib for Evidence-based recommendations on intreated EGFR mutation- osimertinib (Tagrisso) for untreated locally positive non-small-cell lung advanced or metastatic epidermal growth 14th October 2020 Y 12/01/2021 18/11/2020 35 days cancer factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults. NHS England Commissioned TA655 – for Evidence-based recommendations on advanced squamous non- nivolumab (Opdivo) for advanced squamous small-cell lung cancer after 21st October 2020 non-small-cell lung cancer in adults after Y 19/01/2021 18/11/2020 28 days chemotherapy chemotherapy. NHS England Commissioned TA152 – Drug-eluting stents for Evidence-based recommendations on using 18th Nov 2020 the treatment of coronary drug-eluting stents in adults. 16/02/2021 20/01/2021 63 days [updated] artery disease TA71 – Guidance on the use of 18th Nov 2020 Evidence-based recommendations on using 16/02/2021 20/01/2021 63 days coronary stents [updated] coronary artery stents in adults. TA656 – for treating Evidence-based recommendations on secondary progressive multiple siponimod (Mayzent) for treating secondary 18th Nov 2020 Y 16/02/2021 20/01/2021 63 days sclerosis progressive multiple sclerosis in adults. NHS England Commissioned TA657 – Carfilzomib for Evidence-based recommendations on 18th Nov 2020 previously treated multiple carfilzomib (Kyprolis) for previously treated [Updates and Y 16/02/2021 20/01/2021 63 days myeloma multiple myeloma in adults. replaces TA457] NHS England Commissioned TA658 – with Evidence-based recommendations on and isatuximab (Sarclisa) with pomalidomide dexamethasone for treating 18th Nov 2020 and dexamethasone for treating relapsed Y 16/02/2021 20/01/2021 63 days relapsed and refractory and refractory multiple myeloma in adults. multiple myeloma NHS England Commissioned TA659 – Galcanezumab for Evidence-based recommendations on preventing migraine galcanezumab (Emgality) for preventing 18th Nov 2020 Y 16/02/2021 20/01/2021 63 days migraine in adults. CCG Commissioned - Blueteq form required

NICE TA Adherence checklist 2020/2021 ELHE NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Technology appraisal (TA) Y Time to Date of TA Release with this medical condition, as indicated by local Date of local (hyperlinked) e N/A implement NICE decision due decision made s days (90 days)

TA660 – Darolutamide with Evidence-based recommendations on androgen deprivation therapy darolutamide (Nubeqa) for treating for treating hormone-relapsed hormone-relapsed prostate cancer in adults 25th Nov 2020 Y 23/02/2021 20/01/2021 56 days non-metastatic prostate cancer at high risk of developing metastatic disease. NHS England Commissioned TA661 – Pembrolizumab for Evidence-based recommendations on untreated metastatic or pembrolizumab (Keytruda) for untreated unresectable recurrent head metastatic or unresectable recurrent head and neck squamous cell and neck squamous cell carcinoma (HNSCC) 25th Nov 2020 Y 23/02/2021 20/01/2021 56 days carcinoma in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more. NHS England Commissioned NICE is unable to make a recommendation TA662 – in on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung combination for untreated 25th Nov 2020 cancer in adults because AstraZeneca N/A N/A N/A N/A extensive-stage small-cell lung [terminated appraisal] cancer withdrew its evidence submission. We will review this decision if the company decides to make a submission. TA663 - with Evidence-based recommendations on Obinutuzumab for untreated venetoclax (Venclyxto) with obinutuzumab chronic lymphocytic leukaemia 9th December 2020 for untreated chronic lymphocytic Y 09/03/2021 20/01/2021 42 days leukaemia in adults. NHS England Commissioned TA664 – Liraglutide for Evidence-based recommendations on managing overweight and liraglutide (Saxenda) for managing obesity 9th December 2020 overweight and obesity alongside a 09/03/2021 20/01/2021 42 days reduced-calorie diet and increased physical activity in adults. TA665 – for Evidence-based recommendations on treating severe rheumatoid upadacitinib (Rinvoq) for severe active 9th December 2020 Y 09/03/2021 20/01/2021 42 days arthritis in adults. CCG Commissioned - Blueteq form required TA666 – Atezolizumab with Evidence-based recommendations on for treating atezolizumab (Tecentriq) with bevacizumab advanced or unresectable (Avastin) for treating advanced or hepatocellular carcinoma 16th December 2020 unresectable hepatocellular carcinoma in Y 16/03/2021 20/01/2021 35 days adults who have not had previous systemic treatment. NHS England Commissioned TA667 – Caplacizumab with Evidence-based recommendations on plasma exchange and caplacizumab (Cablivi) with plasma for exchange and immunosuppression for treating acute acquired treating acute acquired thrombotic 16th December 2020 Y 16/03/2021 20/01/2021 35 days thrombotic thrombocytopenic thrombocytopenic purpura in adults, and in purpura young people aged 12 years and over who weigh at least 40 kg. NHS England Commissioned TA668 – plus Evidence-based recommendations on for previously encorafenib (Braftovi) plus cetuximab treated BRAF V600E mutation- (Erbitux) for treating BRAF V600E mutation- positive metastatic colorectal 6th January 2021 positive metastatic colorectal cancer in Y 06/04/2021 17/02/2021 42 days cancer adults who have had previous systemic treatment. NHS England Commissioned TA669 – Trifluridine-tipiracil for Evidence-based recommendations on treating metastatic gastric trifluridine–tipiracil (Lonsurf) for treating cancer or gastro-oesophageal 27th January 2021 metastatic gastric cancer or gastro- Y 27/04/2021 17/02/2021 21 days junction adenocarcinoma after oesophageal junction adenocarcinoma in 2 or more therapies adults after 2 or more therapies.

NICE TA Adherence checklist 2020/2021 ELHE NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Technology appraisal (TA) Y Time to Date of TA Release with this medical condition, as indicated by local Date of local (hyperlinked) e N/A implement NICE decision due decision made s days (90 days)

TA670 – for ALK- Evidence-based recommendations on positive advanced non-small- brigatinib (Alunbrig) for anaplastic cell lung cancer that has not lymphoma kinase (ALK)-positive advanced 27th January 2021 Y 27/04/2021 17/02/2021 21 days been treated with an ALK non-small-cell lung cancer that has not been inhibitor previously treated with an ALK inhibitor NHS England Commissioned TA672 -Brolucizumab for Evidence-based recommendations on treating wet age-related brolucizumab (Beovu) for treating wet age- 3rd February 2021 Y 04/05/2021 17/02/2021 14 days macular degeneration [fast related macular degeneration in adults. track] CCG Commissioned - Blueteq form required TA671 – for Evidence-based recommendations on treating severe eosinophilic mepolizumab (Nucala) for treating severe 3rd February 2021 Y 04/05/2021 17/02/2021 14 days asthma [fast track] eosinophilic asthma in adults. NHS England Commissioned TA673 – Niraparib for Evidence-based recommendations on maintenance treatment of niraparib (Zejula) for maintenance advanced ovarian, fallopian treatment of advanced (FIGO stages 3 and tube and peritoneal cancer 4) high-grade epithelial ovarian, fallopian 17thFebruary 2021 Y 18/05/2021 17/03/21 28 days after response to first-line tube or primary peritoneal cancer after platinum-based chemotherapy response to first-line platinum-based chemotherapy in adults. Cancer Drugs Fund TA674 – Pembrolizumab for NICE is unable to make a recommendation untreated PD-L1-positive, on pembrolizumab (Keytruda) for untreated locally advanced or metastatic PD-L1-positive, locally advanced or 17th February 2021 urothelial cancer when metastatic urothelial cancer when cisplatin N/A N/A N/A N/A [terminated appraisal] cisplatin is unsuitable. is unsuitable in adults. This is because Merck Sharp & Dohme did not provide a complete evidence submission. TA675 – Vernakalant for the NICE is unable to make a recommendation rapid conversion of recent on vernakalant (Brinavess) for the rapid onset atrial fibrillation to sinus conversion of recent onset atrial fibrillation 17th February 2021 rhythm to sinus rhythm in adults. This is because N/A N/A N/A N/A [terminated appraisal] Correvio Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission. TA676 – for treating Evidence-based recommendations on moderate to severe filgotinib (Jyseleca) for moderate to severe 24th February 2021 Y 25/05/2021 17/03/2021 21 days rheumatoid arthritis rheumatoid arthritis in adults. CCG Commissioned - Blueteq form required TA677 - Autologous anti- Evidence-based recommendations on CD19-transduced CD3+ cells for autologous anti-CD19-transduced CD3+ cells treating relapsed or refractory for treating relapsed or refractory mantle mantle cell lymphoma 24th February 2021 cell lymphoma in adults who have Y 25/05/2021 17/03/2021 21 days previously had a Bruton’s tyrosine kinase (BTK) inhibitor. Cancer Drugs Fund TA678 - for NICE is unable to make a recommendation treating chronic rhinosinusitis on omalizumab (Xolair) for treating chronic with nasal polyps rhinosinusitis with nasal polyps in adults 24th February 2021 because Novartis Pharmaceuticals did not N/A N/A N/A N/A (terminated appraisal) provide an evidence submission. We will review this decision if the company decides to make a submission. TA679 - Dapagliflozin for Evidence-based recommendations on treating chronic heart failure dapagliflozin (Forxiga) for symptomatic with reduced ejection fraction 24th February 2021 chronic heart failure with reduced ejection Y 25/05/2021 17/03/2021 21 days fraction in adults. CCG Commissioned - Blueteq form required TA185 - Trabectedin for the Evidence-based recommendations on treatment of advanced soft Updated 24th trabectedin (Yondelis) for treating advanced Y 25/05/2021 17/03/21 21 days tissue sarcoma February 2021 soft tissue sarcoma in adults. NHS England Commissioned

NICE TA Adherence checklist 2020/2021 ELHE NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Implementation Summary 2020 - 2021

Total Terminated TA’s TA’s Total 49 12 % % Average “Yes” “N/A” implementation time (days) Adherence statistics for 2020 - 2021 100 100 42

NICE TA Adherence checklist 2020/2021 ELHE